Landos Biopharma, Inc.
LABPNASDAQHealthcare
$22.93
+$0.13(+0.57%)
Market Cap$71675511
P/E Ratio—
52W High$22.94
52W Low$3.145
Landos Biopharma, Inc. (LABP) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LABP · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.02B) | ($0.04B) | ($0.04B) | ($0.03B) | ($0.01B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Change in Working Capital | $0.00B | ($0.01B) | $0.01B | $0.01B | $0.00B |
| Net Cash from Operations | ($0.02B) | ($0.05B) | ($0.03B) | ($0.02B) | ($0.01B) |
| Investing Activities | |||||
| Capital Expenditure | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | $0.00B | ($0.00B) | ($0.17B) | ($0.02B) | ($0.04B) |
| Sales of Investments | $0.01B | $0.08B | $0.12B | $0.04B | $0.00B |
| Net Cash from Investing | $0.01B | $0.07B | ($0.06B) | $0.01B | ($0.04B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.00B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.01B | $0.00B | $0.09B | $0.00B | $0.06B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.02B) | ($0.05B) | ($0.03B) | ($0.02B) | ($0.01B) |
| FCF Margin %(computed) | — | — | -152.78% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Landos Biopharma, Inc. data
About Landos Biopharma, Inc. (LABP) Cash Flow Statement
Landos Biopharma, Inc. generated operating cash flow of ($0.02B) and free cash flow of ($0.02B) for 2023 — a FCF margin of —. Capital expenditure was $0.00B.
Frequently asked questions
LABP · 4 questionsLandos Biopharma, Inc. generated free cash flow of ($0.02B) for 2023, up 55.3% year-over-year.
LABP free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10